Global Press Releases
Navigate within 'Global Press Releases'
Available now! New episode of Sandoz TV
February 13, 2012
Sandoz has just launched its eighth episode and third year of Sandoz TV.
Novartis announces Q4/Full Year 2011 results
Basel, January 25, 2012
Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011
Sandoz initiates two more Phase III biosimilar trials, reinforcing long-term global leadership commitment
Holzkirchen, Germany, January 19, 2012
Sandoz announced today that it has initiated two milestone Phase III clinical trials - one for biosimilar filgrastim (Amgen's Neupogen®) in the US market, the other for its global pegfilgrastim development program (Amgen's Neulasta®).
Sandoz Head Jeff George Named Top "40 Under 40"
Holzkirchen, Germany
Sandoz is pleased to announce that Jeff George, global Head of Sandoz, has been named part of Fortune Magazine’s 2011 Top “40 Under 40”.
New episode of Sandoz TV now available!
October 27, 2011
Sandoz is pleased to announce that it has launched a new, seventh episode of Sandoz TV.
Novartis announces Q3 2011 results
Basel, October 25, 2011
Novartis achieves strong third quarter financial performance and pipeline progress.
Novartis announces Q2 2011 results
Basel, July 19, 2011
Novartis delivers strong financial results and four major approvals in second quarter of 2011
Novartis announces Q1 2011 results
Basel, April 19, 2011
Novartis makes a strong start for the year.
Novartis announces Q4/Full Year 2010 results
Basel, January 27, 2011
Innovation drives Novartis to double-digit growth for 2010
Sandoz announces phase II clinical trial for biosimilar version of leading monoclonal antibody rituximab
Holzkirchen, January 10, 2011
Sandoz announced today that it has begun a phase II clinical trial in patients for biosimilar rituximab (Roche’s Rituxan® / Mabthera®), a leading monoclonal antibody indicated in conditions including non-Hodgkin’s lymphoma and rheumatoid arthritis.
